Durvalumab plus chemotherapy for advanced LCNEC lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of the immunotherapy drug durvalumab (Imfinzi) with standard chemotherapy (etoposide and a platinum drug) as a first treatment for advanced large-cell neuroendocrine carcinoma of the lung. The goal is to see if this combination works better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with a specific type of lung cancer called large-cell neuroendocrine carcinoma (LCNEC).
- Your cancer is either stage III (can't be treated with surgery or radiation) or stage IV (spread), and you haven't had chemotherapy for advanced disease.
- You are in fairly good health: you can care for yourself (ECOG score 0 or 1), weigh more than 66 pounds, and have adequate organ function.
- You have not had prior treatment with immunotherapy drugs like durvalumab (Imfinzi), pembrolizumab (Keytruda), or nivolumab (Opdivo).
- You do not have an active autoimmune disease (like lupus or Crohn's), uncontrolled infections, or other serious medical conditions (like heart disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a new immunotherapy drug (durvalumab) with standard chemotherapy for people with a rare, advanced form of lung cancer called LCNEC. It aims to see if this combination can shrink tumors or slow the cancer’s growth better than chemotherapy alone.
This trial tests a combination of durvalumab (an immunotherapy drug) plus a chemotherapy called XELOX as the first treatment for advanced gastrointestinal neuroendocrine carcinoma (NEC). It aims to see if the combination works better than chemo alone.
This trial tests whether the immunotherapy drug durvalumab can help keep limited-stage small cell lung cancer from coming back after standard treatment. You would receive durvalumab as a 'consolidation' (maintenance) therapy.
This phase 2 trial studies whether durvalumab given with consolidation radiotherapy can help people with extensive-stage small cell lung cancer that has only a few metastases. It builds on initial chemotherapy and immunotherapy response, then targets the chest and limited metastatic spots with radiation.
This Phase 2 study tests durvalumab (an immunotherapy) together with focused, ablative radiation to treat metastatic small cell lung cancer. It may help shrink tumors and improve outcomes, especially when at least one tumor can be safely targeted with this radiation plan.
This trial tests a new combination of durvalumab (an immunotherapy) plus standard chemotherapy for people with advanced small cell carcinoma that started outside the lung and has not been treated before. The goal is to see if this combo works better than chemo alone.
Hear when a new Large Cell Neuroendocrine Carcinoma of the Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.